Pharmaceutical

Evox Therapeutics teams with New York medical school to co-develop AAV vectors

Evox and the Icahn School of Medicine will develop gene delivery vectors for cardiomyocytes for heart disease treatments.

Aug 4, 2023 - 20:00
Evox Therapeutics teams with New York medical school to co-develop AAV vectors
Evox and the Icahn School of Medicine will develop gene delivery vectors for cardiomyocytes for heart disease treatments.
Read the original article

Tags:

Previous Article

Mesoblast plans new GvHD trial after another FDA rejection

Next Article

Accord gears up to commercialise Hipra’s Covid-19 vaccine in the UK

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and obesity in SUMMIT

AHA 2024: Tirzepatide improves outcomes for major heart...

Nov 19, 2024

STAT+: After a lull, the pace of FDA authorization of AI-enabled medical devices is rising

STAT+: After a lull, the pace of FDA authorization of A...

Oct 20, 2023

In absence of Roe v. Wade, an abortion doctor dwells on all the patients she does not see

In absence of Roe v. Wade, an abortion doctor dwells on...

Jun 24, 2023